Universitaetsklinikum Schleswig-Holstein AöR
Verified site
Kiel, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
Fibromyalgia syndrome is a long‑lasting condition that causes widespread muscle pain, tiredness, and problems with sleep. The study will test a new oral spray called AP707, whose active ingredient is adezunap, and compare it with a placebo that looks the same but does not contain the active drug.
The main aim of the trial is to see whether the medication can reduce the level of pain and improve other symptoms of the condition. After a short “washout” period, during which participants stop other pain medicines, they will receive either the study drug or the placebo for several weeks. Throughout the study, participants will attend a few clinic visits where they will rate their pain on a simple 0‑to‑10 scale, answer questions about daily function, and have basic health checks such as blood pressure and blood tests.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
9 criteria
Scoring on the assessment tools as either:
12 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
AP707 is an experimental medication being tested for the treatment of fibromyalgia. It is given as an oral spray or suspension that is placed in the mouth, where it is absorbed through the lining of the mouth. The drug contains an active ingredient called adezunap, which is being studied to see if it can reduce the widespread pain, fatigue, and sleep problems that people with fibromyalgia often experience. In this trial, participants receive AP707 to find out whether it can safely improve their symptoms compared with not receiving the active drug.
This is an inert oral spray/suspension used only as a control in the study. It contains no active drug and therefore has no therapeutic effect or approved medical use. Placebos are commonly employed in clinical trials to compare the effects of the real medication. Because it has no active ingredient, it has no mechanism of action or pharmacological class.
AP707 is an oral mucosal spray/suspension delivering 19.8 mg of adezunap, taken by spraying onto the inside of the mouth. The product is currently in a phase II clinical trial and has not yet been approved for any medical use. It is being tested to relieve the pain and other symptoms of fibromyalgia syndrome. Adezunap works by modulating pain‑signaling molecules in the nervous system, and it is classified as a non‑opioid analgesic (ATC code N02BG10).
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.